Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Change in Acquisitions & Divestments (2017 - 2019)

Cogent Biosciences (COGT) has 2 years of Change in Acquisitions & Divestments data on record, last reported at $8.0 million in Q2 2019.

  • For Q2 2019, Change in Acquisitions & Divestments rose 19.34% year-over-year to $8.0 million; the TTM value through Dec 2019 reached $23.0 million, down 39.02%, while the annual FY2025 figure was $289.2 million, 1.78% down from the prior year.
  • Change in Acquisitions & Divestments reached $8.0 million in Q2 2019 per COGT's latest filing, down from $15.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $15.0 million in Q4 2018 and bottomed at $6.0 million in Q1 2018.